The U.S. CDC has undergone leadership upheaval with director Susan Monarez’s reported dismissal amid consistent internal resignations citing politicization and censorship concerns. Concurrently, the FDA approved Sanofi’s BTK inhibitor rilzabrutinib for immune thrombocytopenia, while issuing complete response letters for Telix’s renal cancer imaging agent Zircaix and Outlook Therapeutics’ antivascular AMD therapy. In biotech leadership, Sanofi appointed Marcia Kayath as chief medical officer. Political and regulatory developments continue to shape public health policy and biopharma landscapes, affecting corporate strategies and compliance.